betaxolol has been researched along with Hyperpigmentation in 2 studies
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Betaxolol ophthalmic solution has been associated with periocular skin hyperpigmentation." | 7.69 | Betaxolol-associated hyperpigmentation of the fingers in a patient with unrelated contact dermatitis. ( Adams, DR; Marks, JG, 1997) |
| "Betaxolol ophthalmic solution has been associated with periocular skin hyperpigmentation." | 3.69 | Betaxolol-associated hyperpigmentation of the fingers in a patient with unrelated contact dermatitis. ( Adams, DR; Marks, JG, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McCarey, BE | 1 |
| Kapik, BM | 1 |
| Kane, FE | 1 |
| Adams, DR | 1 |
| Marks, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation[NCT00705757] | Phase 4 | 89 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Periocular skin color was measured with the Minolta Chroma Meter CR-400 and the L*a*b* system, also known as Commission Internationale de l'Eclairage. This is a well-accepted unit of measurement in which L* corresponds to brightness and a* and b* correspond to chromaticity.~Measurements were taken at baseline and 1 year. Data from each time point and each location (upper and lower eyelids or cheeks/face) were averaged, and subtracted from the baseline value for that location. Six predetermined areas on and around the upper and lower eyelid and 2 areas of the face/cheek were measured.Upper and lower eyelid values were averaged and reported as single value for each location ie;-upper eyelids, lower eyelid and cheek/face. A decrease in luminance indicates increased pigmentation at the site of measurement." (NCT00705757)
Timeframe: one year
| Intervention | L*a*b* (Mean) | ||
|---|---|---|---|
| Upper Lid | Lower Lid | Cheek/Face | |
| Lumigan | -0.90 | -0.37 | 0.30 |
| Travatan | -0.90 | 0.17 | 0.51 |
| Xalatan | -1.42 | 0.48 | 0.55 |
1 trial available for betaxolol and Hyperpigmentation
| Article | Year |
|---|---|
Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Betaxolol; Dinoprost; Double-Blind Method; | 2004 |
1 other study available for betaxolol and Hyperpigmentation
| Article | Year |
|---|---|
Betaxolol-associated hyperpigmentation of the fingers in a patient with unrelated contact dermatitis.
Topics: Administration, Oral; Allergens; Antihypertensive Agents; Betaxolol; Dermatitis, Allergic Contact; D | 1997 |